Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Schedule Of Available For Sale Securities [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument Financial Instrument [Axis] Segment Reporting [Abstract] Common stock, par value of $0.0001 per share; 300,000,000 shares authorized as of June 30, 2026, and December 31, 2025, respectively, and 122,905,756 and 96,914,418 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Restatement Determination Date Restatement Determination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Measurement Frequency [Axis] Measurement Frequency [Axis] Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Class of Warrant or Right [Table] Class of Warrant or Right [Table] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Marketable securities, current: Debt Securities, Available-for-sale, Current [Abstract] Debt Securities, Available-for-sale, Current Leases [Abstract] Leases [Abstract] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Nonrefundable upfront payment Non Refundable Upfront Payment Non refundable upfront payment. Property, Plant, and Equipment [Abstract] Property, Plant, and Equipment [Abstract] Entity Address, State or Province Entity Address, State or Province Stock options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Non-Qualified Stock Options Non-Qualified Stock Options [Member] Non-Qualified Stock Options Shares outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Weighted-average number of shares used in computed net loss per share − basic Weighted Average Number of Shares Outstanding, Basic Net accretion of discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Other (in shares) Adjustments To Additional Paid In Capital Other Shares Adjustments to additional paid in capital other shares. Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Noncurrent Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Noncurrent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Interest and other income, net Interest and Other Income Deferred revenue Increase (Decrease) in Deferred Revenue Entity Address, City or Town Entity Address, City or Town Number of targeted protein degradation Number Of Targeted Protein Degradation Number of targeted protein degradation. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Marketable securities, non-current: Debt Securities, Available-for-sale, Noncurrent [Abstract] Debt Securities, Available-for-sale, Noncurrent Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Units vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount At-The-Market At-The-Market [Member] At-The-Market Level 2 Fair Value, Inputs, Level 2 [Member] Other income, net: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Merck, KGaA Agreement Merck, KGaA Agreement [Member] Merck, KGaA Agreement Other Adjustments to Additional Paid in Capital, Other Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Amount eligible to receive Contracts Receivable, Claims and Uncertain Amounts Recently issued accounting standards New Accounting Pronouncements, Policy [Policy Text Block] Capital expenditures in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Segment Reporting Segment Reporting [Table Text Block] Use of estimates Use of Estimates, Policy [Policy Text Block] Summary of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Research and development milestones Research And Development Milestones [Member] Research and development milestones. Exercise price of warrants or rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Property and equipment Property, Plant, and Equipment [Text Block] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Stockholders' equity Equity [Text Block] Security Exchange Name Security Exchange Name Research expenses Research Expenses Research Expenses Stock options granted, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Purchases of marketable securities Payments to Acquire Marketable Securities Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Operating lease liability, current Operating Lease, Liability, Current Summary of property and equipment Property, Plant, and Equipment [Table Text Block] Loss per share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Proceeds from maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Share-based compensation, number of common stock issuable per RSU vested (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Common Stock Issuable Per R S U Vested Share-based compensation arrangement by share-based payment award, number of common stock issuable per RSU vested. Schedule of financial information related to collaboration and license agreements Financial Information Related To Collaboration And License Agreements Table [Table Text Block] Financial information related to the collaboration and license agreements. Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Option exercise fees Option Exercise Fee Option exercise fee. Marketable securities Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Roche Degrader-Antibody Conjugate Collaboration and License Agreement Roche Degrader-Antibody Conjugate Collaboration and License Agreement [Member] Roche Degrader-Antibody Conjugate Collaboration and License Agreement Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Warrants issued (in shares) Class Of Warrant Or Right, Issued, Shares Class Of Warrant Or Right, Issued, Shares Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Noncurrent Company Selected Measure Name Company Selected Measure Name Sale of Stock Sale of Stock [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Unrealized loss on marketable securities Change in unrealized loss, net on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Cash flows used in operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average number of shares used in computed net loss per share − diluted Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent U.S. Treasury securities US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Transaction price from closing of the stock purchase agreement Transaction Price From Closing of the Stock Purchase Agreement Transaction Price From Closing of the Stock Purchase Agreement Premium from issuance of common stock Premium From Issuance Of Common Stock Premium From Issuance Of Common Stock Cash paid for leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Options to purchase common stock Options To Purchase Common Stock [Member] Options to purchase common stock. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Proceeds from exercise of warrants Proceeds from Warrant Exercises Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Discovery, Regulatory, and Commercial Milestones Discovery, Regulatory, and Commercial Milestones [Member] Discovery, Regulatory, and Commercial Milestones Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants Betta Agreements Betta Agreement [Member] Betta Agreement All Executive Categories All Executive Categories [Member] Number of performance obligations Number of Performance Obligations Number of Performance Obligations U.S. government debt securities US Government Debt Securities [Member] Operating lease liability Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Depreciation expense Depreciation Antidilutive Securities Antidilutive Securities [Axis] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Right-of-use asset Operating Lease, Right-of-Use Asset Summary of allocation of transaction price Summary Of Allocation Of Total Transaction Price And Unsatisfied Transaction Price Table [Table Text Block] Summary of allocation of total transaction price and unsatisfied transaction price. Number of potential research and development targets Number Of Potential Research and Development Targets Number Of Potential Research and Development Targets Exercised Warrant Or Right Class [Domain] Exercised Warrant Or Right Class [Domain] Exercised Warrant Or Right Class [Domain] Number of targets Number Of Targets Number of targets. Renewal term Lessee, Operating Lease, Renewal Term Schedule of basic and diluted loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Biogen Agreement Biogen Agreement [Member] Biogen agreement. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Duration of trading day volume weighted average closing price Sale Of Stock, Duration of Trading Day Volume Weighted Average Closing Price Sale Of Stock, Duration of Trading Day Volume Weighted Average Closing Price Segment reporting Segment Reporting [Text Block] Marketable securities Investment in Debt and Equity Securities and Other Trading Assets [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Addition to the transaction price Collaborative Arrangement, Addition To The Transaction Price Collaborative Arrangement, Addition To The Transaction Price Performance-Accelerated Restricted Stock Units Performance-Accelerated Restricted Stock Units [Member] Performance-Accelerated Restricted Stock Units Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Income Statement Location Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Class A Warrants Class A Warrants [Member] Class A Warrants Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from issuance of common stock from at-the-market equity offering Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Accrued compensation and benefits Accrued Employee Benefits, Current Exercise Price Award Exercise Price Cash flows provided by (used in) investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Recurring Fair Value, Recurring [Member] Segment Reporting [Line Items] Segment Reporting [Line Items] Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report One-time sales-based payments One Time Sales Based Payments [Member] One-time sales-based payments. Exercised Warrant Or Right Class [Axis] Exercised Warrant Or Right Class [Axis] Exercised Warrant Or Right Class Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Amount eligible to receive Collaborative Arrangement, Potential Proceeds From Collaboration Collaborative Arrangement, Potential Proceeds From Collaboration Summary of marketable securities Marketable Securities [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Consideration received on transaction Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Accrued research and development Accrued Research And Development Current Accrued research and development, current. Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Total other income, net Non-operating income Nonoperating Income (Expense) Share price, minimum threshold for consecutive trading days Share Price, Minimum Threshold For Consecutive Trading Days Share Price, Minimum Threshold For Consecutive Trading Days Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Marketable securities, non-current Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent Insider Trading Policies and Procedures [Line Items] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Other Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Total anti-dilutive common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of diluted net loss per share attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Less: accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Number of consecutive trading days prior to the date of notice of mandatory exercise Class Of Warrant Or Right, Number Of Consecutive Trading Days Prior To The Date Of Notice Of Mandatory Exercise Class Of Warrant Or Right, Number Of Consecutive Trading Days Prior To The Date Of Notice Of Mandatory Exercise Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Issuances of common stock under 2020 ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Upfront fees Upfront Fees Upfront fees. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating expenses: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] City Area Code City Area Code Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Warrants Warrants And Rights Outstanding [Text Block] Warrants And Rights Outstanding Reduction in carrying amount of right-of-use asset Operating Lease, Right-of-Use Asset, Periodic Reduction Research and development targets Research And Development Targets [Member] Research and development targets. Name Forgone Recovery, Individual Name Expected to be recognized over a weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Underwritten Offering Underwritten Offering [Member] Underwritten Offering Preferred stock, shares issued Preferred Stock, Shares Issued Operating Segments Operating Segments [Member] Stock options granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-based compensation Share-Based Payment Arrangement [Text Block] Issuance of common stock under 2020 ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock pursuant to the at-the-market equity program, net (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Issuance of common stock upon exercise of warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Total stock-based compensation expense Share-Based Payment Arrangement, Expense Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issuance of common stock upon exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Research, development and commercial milestone payments Research Development And Commercial Milestone Payments [Member] Research, development and commercial milestone payments. Revenue recognized that was included in the contract liability at the beginning of the period Contract with Customer, Liability, Revenue Recognized Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accumulated Deficit Retained Earnings [Member] Operating lease liability, net of current Operating Lease, Liability, Noncurrent Total operating expenses Operating Expenses Money market funds Money Market Funds [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate debt securities Corporate Debt Securities [Member] Net loss per share − diluted (in dollars per share) Earnings Per Share, Diluted Number of potential targets Number Of Potential Targets Number of potential targets. Entity Current Reporting Status Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Prepaid expenses and other current and long-term assets Increase (Decrease) in Prepaid Expense and Other Assets Written notice period for termination of agreement Notice Period For Termination Of Agreement Notice period for termination of agreement. MKDG Agreement MKDG Agreement [Member] MKDG Agreement Research and development Research and Development Expense Adjustments to reconcile net loss to cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows provided by (used in) financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Revenue from collaboration agreements Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Total property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Financial Instruments Financial Instruments [Domain] Additional upfront consideration received Additional Upfront Consideration Additional upfront consideration. Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Issuance of common stock pursuant to the at-the-market equity program, net Issuance and sale of common stock Stock Issued During Period, Value, New Issues Trading days prior to the effective date of the Stock Purchase Agreement Sale Of Stock, Trading Days Prior To The Effective Date Of The Stock Purchase Agreement Sale Of Stock, Trading Days Prior To The Effective Date Of The Stock Purchase Agreement Class Of Warrant Or Right [Roll Forward] Class Of Warrant Or Right [Roll Forward] Class Of Warrant Or Right Roche DAC Agreement Roche DAC Agreement [Member] Roche DAC Agreement Segment Reporting [Table] Segment Reporting [Table] Computer equipment Computer Equipment [Member] Sale of Stock Sale of Stock [Axis] Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Estimated transaction price Collaborative Arrangement, Estimated Transaction Price Collaborative Arrangement, Estimated Transaction Price Research agreement, period Research And Development Agreement Period Research and development agreement period. Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Office equipment Office Equipment [Member] Loss from operations Operating Income (Loss) Class B Warrants Class B Warrants [Member] Class B Warrants Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Transaction Price Unsatisfied Transaction Price Unsatisfied To Performance Obligation Transaction price unsatisfied to performance obligation. Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued Common Stock, Shares, Issued Measure: Measure [Axis] Total consideration received on transaction, potential expected Sale of Stock, Total Consideration Received On Transaction, Potential Expected Sale of Stock, Total Consideration Received On Transaction, Potential Expected Equity Components Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service Product and Service [Domain] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Number of shares retained to cover statutory minimum withholding taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Property Plant And Equipment [Line Items] Property, Plant, and Equipment [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Restated Roche Agreement Restated Roche Agreement [Member] Restated Roche agreement. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other Other Liabilities, Current Other assets Other Assets, Noncurrent Document Type Document Type Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of revenue from collaboration agreements Revenue From Collaboration Agreements Table [Table Text Block] Revenue from collaboration agreements. Fair Value as of Grant Date Award Grant Date Fair Value Transaction price allocated to performance obligation Transaction Price Allocated Transaction Price Allocated To Performance Obligation Transaction price allocated to performance obligation. Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest Summary of significant accounting policies Significant Accounting Policies [Text Block] Upfront payment Upfront Payment Upfront payment. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred revenue, net of current Contract with Customer, Liability, Noncurrent Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (see Note 12) Commitments and Contingencies Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Property and equipment Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Sale of stock, value authorized for sale Sale Of Stock, Value Authorized For Sale Sale Of Stock, Value Authorized For Sale Executive Category: Executive Category [Axis] Leasehold improvements Leaseholds and Leasehold Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Schedule of financial assets measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Marketable securities: Marketable Securities [Abstract] Award Type Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Class of Warrant or Right, Outstanding Fair value measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] U.S. government debt securities US Government Agencies Debt Securities [Member] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] PEO Name PEO Name Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Contract with customer, liability Deferred revenue, total Contract with Customer, Liability Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-Term Investments Adjustments or reconciling items Segment Reporting, Other Segment Item, Amount Long-Lived Asset, Class Long-Lived Asset, Class [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Restated Roche Agreement And Biogen License Agreement Restated Roche Agreement And Biogen License Agreement [Member] Restated Roche Agreement And Biogen License Agreement Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Development expenses Development Expenses Development Expenses Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Pre-Funded Warrants And Class A and Class B Warrants Pre-Funded Warrants And Class A and Class B Warrants [Member] Pre-Funded Warrants And Class A and Class B Warrants Nature of the business and basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Expected consideration to be received from manufactured clinical supply Expected Consideration To Be Received From Manufactured Clinical Supply Expected Consideration To Be Received From Manufactured Clinical Supply Regulatory milestone achieved Collaborative Arrangement, Regulatory Milestone Achieved Collaborative Arrangement, Regulatory Milestone Achieved Leases Lessee, Operating Leases [Text Block] Net loss per share − basic (in dollars per share) Earnings Per Share, Basic Payments for repurchase of common stock for tax withholding Payments for Repurchase of Common Stock Deferred revenue, current Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Number of remaining research and development targets Number Of Remaining Research And Development Targets Number Of Remaining Research And Development Targets Unaudited interim financial information Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited interim financial information. Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Stock repurchase program, premium percentage Sale Of Stock, Premium Percentage Sale Of Stock, Premium Percentage Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Current Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Current Equity Awards Adjustments Equity Awards Adjustments [Member] Collaboration and license agreements Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Stock Options Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Tabular List, Table Tabular List [Table Text Block] Restricted cash Less: restricted cash Restricted Cash and Cash Equivalent, Noncurrent Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] General and administrative General and Administrative Expense Long-Lived Asset, Class Long-Lived Asset, Class [Domain] Schedule of supplemental financial information related to collaboration and license agreements Supplemental Financial Information Related To Collaboration And License Agreements Table [Table Text Block] Supplemental financial information related to collaboration and license agreements. Price per share (in dollars per share) Sale of Stock, Price Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Accounts Receivable Receivables, Net, Current Accrued expenses and other current liabilities: Accrued Liabilities and Other Liabilities [Abstract] Reportable Segment Reportable Segment [Member] Reportable Segment Schedule Of Property Plant And Equipment [Table] Property, Plant, and Equipment [Table] Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of June 30, 2026 and December 31, 2025, respectively Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Class of Stock [Domain] Class of Stock [Domain] Roche Agreement Roche Agreement [Member] Roche agreement. Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Marketable securities, current Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total cash equivalents and marketable securities Assets, Fair Value Disclosure Name Measure Name Income taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Annual research plan payments receivables Annual Research Plan Payments Receivables Annual research plan payments receivables. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents at end of the period Cash and Cash Equivalent Drug Application Approval Drug Application Approval [Member] Drug Application Approval Company Selected Measure Amount Company Selected Measure Amount Depreciation and amortization expense Depreciation, Depletion and Amortization Option rights Option Rights [Member] Option rights. Entity Address, Address Line Two Entity Address, Address Line Two Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Income tax provision (benefit) Income Tax Expense (Benefit) Class A and Class B Warrants Class A and Class B Warrants [Member] Class A and Class B Warrants Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Merck Agreement Merck Agreement [Member] Merck Agreement Award Timing Method Award Timing Method [Text Block] Consolidation Consolidation, Policy [Policy Text Block] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Proceeds from exercise of stock options Proceeds from Stock Options Exercised Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Potential mandatory exercise, minimum period after issuance Class Of Warrant Or Right, Potential Mandatory Exercise, Minimum Period After Issuance Class Of Warrant Or Right, Potential Mandatory Exercise, Minimum Period After Issuance Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Lead series identification achievement Lead Series Identification Achievement [Member] Lead series identification achievement. Supplemental disclosures of non-cash investing activities: Other Noncash Investing and Financing Items [Abstract] Issuance of common stock upon exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Biogen Research and License Agreement Biogen Research and License Agreement [Member] Biogen license agreement Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Collaborative Arrangement [Member]